Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01695954 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01695954 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 34 participants.
The verdict
NCT01695954, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The main goal of this study is to determine how taking efavirenz affects the levels of pitavastatin in the bloodstream when both drugs are taken together and to see how darunavir with ritonavir affects the levels of pitavastatin in the bloodstream. Secondary goals are to see how taking pitavastatin affects the levels in the blood of efavirenz when both drugs are taken together and to see how taking pitavastatin affects the levels in the blood of darunavir.
Interventions
- DRUG Ritonavir
- DRUG Efavirenz
- DRUG Darunavir
- DRUG Pitavastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01695954
The ClinicalTrials.gov registry entry for NCT01695954 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ritonavir is the first listed.
NCT01695954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01695954 about?
NCT01695954 is a clinical study titled "Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz". The main goal of this study is to determine how taking efavirenz affects the levels of pitavastatin in the bloodstream when both drugs are taken together and to see how darunavir with ritonavir affects the levels of pitavastatin in the bloodstream. Secondary goals are to see how taking pitavastatin ...
What is the current status of trial NCT01695954?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2012-05. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01695954?
The interventions under investigation include: Ritonavir (DRUG), Efavirenz (DRUG), Darunavir (DRUG), Pitavastatin (DRUG).
Who is sponsoring clinical trial NCT01695954?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.